Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience

The treatment of advanced urothelial carcinoma (UC) has dramatically changed with the advent of immune checkpoint inhibitors that disrupt the T-cell inhibitory interaction between the programmed cell death (PD)-1 receptor and its ligand (PD-L1). Pembrolizumab, a highly specific, monoclonal antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Crist, Michael, Iyer, Gopa, Hsu, Miles, Huang, William C., Balar, Arjun V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452591/
https://www.ncbi.nlm.nih.gov/pubmed/31057668
http://dx.doi.org/10.1177/1756287219839285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452591/
https://www.ncbi.nlm.nih.gov/pubmed/31057668
http://dx.doi.org/10.1177/1756287219839285

Ejemplares similares